Generated by AI
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines for kidney, cardiovascular, and related metabolic diseases, including obesity. The company uses its human genetics-driven Compass platform to identify disease-linked genetic variants and translate those insights into targeted drug candidates. Its current pipeline includes oral programs aimed at genetically defined kidney disorders, reflecting a strategy centered on precision medicine and biologically validated pathways. Maze Therapeutics operates from South San Francisco, California, and is positioned within the broader biotechnology sector as a developer of novel therapies for patients with renal and metabolic conditions.
Website171 Oyster Point Blvd
South San Francisco, CA, 94080
United States
The latest articles about MAZE.
Summary of Mar 25's posts. Generated by AI.
No summary yet.
Summary of Sep 11's posts. Generated by AI.
No summary yet.
Summary of Sep 12's posts. Generated by AI.
Investors talking about MAZE also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.